Physician profile
Renee Cotter
NPI 1861569428
$4,190.02
in general payments reported to CMS, 2019-2025
32 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $739 · 2021: $1,363 · 2022: $519 · 2023: $280 · 2024: $121 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,002.85 | 2019-2024 | |
| Abbvie INC. | $818.55 | 2019-2023 | Liletta |
| Therapeuticsmd, INC. | $439.54 | 2019-2021 | |
| Ascend Therapeutics US, LLC | $271.63 | 2019-2021 | |
| Astellas Pharma US INC | $245.74 | 2019-2024 | Veozah |
| Myovant Sciences INC. | $186.43 | 2021-2022 | |
| Exact Sciences Corporation | $167.68 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $119.99 | 2019-2024 | Prolia, Evenity |
| Mayne Pharma Commercial LLC | $106.13 | 2021-2025 | |
| Radius Health, INC. | $96.08 | 2019-2020 | |
| Allergan, INC. | $88.49 | 2019-2020 | |
| Medtronic, INC. | $75.89 | 2023 | Ligasure |
| Merck Sharp & Dohme LLC | $61.12 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.49 | 2019-2020 | |
| Duchesnay USA Incorporated | $51.20 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $49.12 | 2020-2021 | |
| Organon LLC | $46.14 | 2021-2022 | |
| Amag Pharmaceuticals, INC. | $43.32 | 2019 | |
| Horizon Therapeutics Plc | $39.56 | 2019-2021 | |
| Boston Scientific Corporation | $23.21 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.17 | 2022 | |
| Daiichi Sankyo INC. | $21.92 | 2021 | |
| Roche Diagnostics Corporation | $20.46 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.16 | 2021 | |
| Heartflow, INC. | $18.78 | 2024 | |
| Mission Pharmacal Company | $17.73 | 2019 | |
| Vertical Pharmaceuticals, LLC | $17.59 | 2019 | |
| Lupin INC. | $14.94 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.78 | 2025 | Austedo Xr |
| Millicent US INC | $13.44 | 2024 | Intrarosa, Femring |
| Virtus Pharmaceuticals LLC | $12.84 | 2021 | |
| Evofem Biosciences, INC. | $12.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Cotter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.